Citations

Clear

4207 citation(s) found for "Yu, Chen".

Abstract 1956: miR-181d degradation mediated genetic heterogeneity and acquired resistance
Ramakrishnan, Valya, Akers, Johnny, Nguyen, Thien , Wang, Aaron , Adhikari, Bandita, Hirshman, Brian R. , Hua, Wei , Ying, Mao, Nitta, Masayuki, Chen, Clark C. , Li, Jie , Sarkaria, Jann N. , Hua, Wei, Ying, Mao, Jiang, Tao , Carter, Bob S.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 1956-1956

10.1158/1538-7445.am2018-1956 Get It

Abstract When unrepaired, alkylated DNA can induce cell death or trigger mutagenesis. Cellular capacity for repair of these lesions by O6-methylguanine methyltransferase (MGMT) dictates the equilibrium between cell viability and genetic diversity. Treatment of glioblastoma cells with temozolomide (TMZ) induced ATM- and Rad3-related (ATR) kinase dependent polyribonucleotide nucleotidyltransferase 1 (PNPT1) degradation of miR-181d. miR-181d suppresses MGMT expression; its degradation increases the mean MGMT expression of the cell population. miR-181d degradation also magnifies the cell-to-cell variability in MGMT expression, expanding the genetic heterogeneity of the population. This expanded heterogeneity enhances the “fitness” of the population and constitutes a novel form of chemotherapeutic resistance. These effects can be suppressed by overexpression of miR-181d, suggesting miRNA delivery as a strategy for glioblastoma therapy. To characterize the mechanism of acquired resistance, we profiled the expression of 2400 miRNAs before and after TMZ treatment. In independent patient-derived neurosphere lines, the majority of miRNAs remained unchanged after treatment. However, miR-181d was consistently suppressed after TMZ treatment. Our previous work demonstrated miR-181d as the master regulator of MGMT. We confirmed TMZ-induced suppression of miR-181d using independent in vitro and in vivo models as well as matched pre- and post-TMZ treated clinical specimens. TMZ-induced miR-181d suppression persisted after transcriptional inhibition, suggesting degradation as the primary mechanism. We performed an siRNA screen and identified polyribonucleotide nucleotidyltransferase 1 (PNPT1) as the gene responsible for miR-181d degradation. CRISPR inactivation of PNPT1 eliminated TMZ-induced suppression of miR-181d; this was rescued by wild-type PNPT1 but not by PNPT1 harboring RNAse-inactivating mutations. TMZ-induced degradation of miR-181d requires ATR kinase. Silencing or inhibition of ATR eliminated binding of PNPT1 to miR-181d and prevented degradation of miR-181d. TMZ-sensitizing effects of ATR inhibition were reversed by anti-miR-181d, suggesting miR-181d is essential in this process. In addition to elevating the mean MGMT expression of the population, single-cell analysis revealed that miR-181d degradation broadened the cell-to-cell variability in MGMT expression in vitro. In matched clinical pre- and post-TMZ treated specimens, variability in MGMT expression was significantly elevated in post-TMZ samples. This was recapitulated using The Cancer Genome Atlas (TCGA) database. We propose that miR-181d degradation-mediated expansion of genetic heterogeneity enhances the “fitness” of the population, constituting a novel form of chemotherapeutic resistance. These effects are suppressed by miR-181d overexpression, suggesting miRNA delivery as a strategy for glioblastoma therapy. Citation Format: Valya Ramakrishnan, Johnny Akers, Thien Nguyen, Aaron Wang, Bandita Adhikari, Brian Hirshman, Jie Li, Jann Sarkaria, Wei Hua, Mao Ying, Masayuki Nitta, Tao Jiang, Bob Carter, Clark C. Chen. miR-181d degradation mediated genetic heterogeneity and acquired resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1956.
Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology
Chen, Alice P. , O’Dwyer, Peter J. , Harris, Lyndsay N. , Conley, Barbara A. , Williams, Mickey, Kumar, Shaji , Mitchell, Edith P. , Gatsonis, Constantine, Shankar, Lalitha , Arteaga, Carlos L. , Iafrate, A. John , Sklar, Jeffrey , Little, Richard F. , Hamilton, Stanley R. , Gray, Robert J. , Li, Shuli , McShane, Lisa M. , Rubinstein, Larry , Lee, Susanna I. , Zwiebel, James A. , Caimi, Paolo F. , Flaherty, Keith T.

Mayo Clinic

Molecular Cancer Therapeutics | August 17, 2018 | Volume: 17 | Issue: 1_Supplement | Pages: PL03-01-PL03-01

10.1158/1535-7163.targ-17-pl03-01 Get It

Abstract Oncology has undergone major changes in systemic treatment options, from chemotherapy to antiangiogenic agents to tyrosine-kinase inhibitors to immunotherapy. Historically, a therapeutic agent is tested in separate trials as monotherapy or combined with investigational or approved agents/modalities, to determine antitumor activity in each histology based on the premise that each histology responds differently to the same treatment. This paradigm is time consuming and may or may not make use of molecular characterization to test each agent in each histology. However, with the expansion of biologic understanding and development of various biomarkers, e.g., estrogen receptor and Her 2 amplification, we move beyond the basic paradigm of general histology to one in which treatment is based upon molecular characteristics of the tumor. Examples of recent discoveries from this more modern paradigm are (1) multiple histologies sharing a common molecular profile and (2) a subset within a single histology having a given molecular characteristic. Various agents have been tested singularly in terms of molecular aberrations and histology, e.g., ALK inhibitors and NSCLC. However, with the rapid increase in the number of targeted agents in development, more facile and efficient clinical trial designs are needed. The National Cancer Institute (NCI) and ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) collaborated in designing the Molecular Analysis for Therapy Choice trial (NCI-MATCH or EAY131), the first large-scale signal-finding precision medicine oncology trial in the United States to incorporate centralized NGS testing to direct patients to parallel (nonrandomized) phase II treatment arms under a master protocol. The trial is being conducted by the NCI National Clinical Trials Network (NCTN), with ECOG-ACRIN leading the trial. More than 100 investigators from across the NCTN adult cancer-oriented member groups (Alliance for Clinical Trials in Oncology, ECOG-ACRIN, NRG Oncology, and SWOG) have worked collaboratively to design and lead what is currently 30 treatment arms (subprotocols), with more arms in development. Wide-scale NCTN investigator involvement ensures use of the latest knowledge to define the actionable mutations required for eligibility and to make evidence-based selections of experimental agents. In NCI-MATCH, patients are assigned treatment based on the genomic alterations found in their tumors through genomic sequencing and other tests at the time of initial enrollment for screening. Unlike other phase II trials, each arm is open to advanced solid tumors, lymphomas, or myeloma that share a set of molecular aberrations, not restricted to a single histology. This strategy accommodates and encourages enrollment of rare tumors for which there are often no standard treatments and limited clinical trial options. NCI-MATCH has 10-30 concurrent treatment arms available to patients at any given time, testing both investigational agents and FDA-approved drugs for new indications. Most treatment arms have an enrollment goal of 35 patients, with some arms that address tumor gene variants of higher prevalence expanded to 70 patients. Together, the NCTN and NCI Community Oncology Research Program provide infrastructure for many clinical sites (>1100) to participate, providing ready access to physicians and patients; screening enrollment has occurred in all 50 states in the U.S, the District of Columbia, and Puerto Rico. A specific assay was developed for the trial (the MATCH assay), and a laboratory network was organized to rapidly process the tissue and efficiently interrogate for mutations. NCI and ECOG-ACRIN statisticians developed the analysis plan and are currently maintaining data that are closely monitored by safety experts for any adverse event signals. Lastly, a bioinformatics system (MATCHbox) was developed to coordinate molecular data collection and support rule-based decision-making based on those data. Because genomics in oncology is rapidly expanding and evolving, NCI-MATCH required flexibility to accommodate brisker screening accrual than anticipated, and adaptation to constantly emerging information about new drugs and new molecular alterations. The goal to sequence the tumors of 6,000 patients with NCI funding was achieved two years ahead of schedule, but that cohort was not sufficient to fill all the arms—in particular, those aimed at the most rarely occurring tumor gene aberrations. Currently, the goal for the trial is to complete the open treatment arms by allowing for designated commercial and academic laboratories to notify ordering physicians when genomic tests they ordered to guide clinical care indicate a potential eligibility to a NCI-MATCH arm with a rare variant and allow for enrollment to the relevant treatment subprotocol if the patient meets all subprotocol eligibility criteria. The tissue confirmation of the molecular abnormality on the MATCH assay by the central laboratories will be accomplished after subprotocol enrollment so that patient treatment will not be delayed for confirmation. A demonstration project is now under way to test the applicability of this approach and potentially develop common standards for future use. With tumor sequencing becoming a more and more common practice in oncology, this may allow patients with mutations of low prevalence to have investigational treatment options. NCI-MATCH is expanding its panel and definition of actionable mutations to allow greater flexibility to incorporate in real time new mutations supported with adequate levels of evidence. The valuable genomic and clinical outcome data collected in the trial will permit evaluation of efficacy of targeting certain actionable mutations with a specific agent. In addition, biospecimens are being collected to build a rich resource for conducting auxiliary biology studies that may answer questions about prevalence of mutations in the metastatic setting, prevalence of mutations in rare histologies, and resistance mechanisms of various targeted therapy. At this meeting, two abstracts will provide an overall trial update and present information about the prevalence of mismatch repair deficiency (dMMR) in the centrally screened population. Citation Format: Alice P. Chen, Peter J. O'Dwyer, Lyndsay Harris, Barbara A. Conley, Stanley R. Hamilton, Mickey Williams, Robert J. Gray, Shuli Li, Lisa M. McShane, Lawrence V. Rubinstein, Susanna I. Lee, Shaji Kumar, Edith P. Mitchell, James A. Zwiebel, Constantine A. Gatsonis, Lalitha K. Shankar, Paolo F. Caimi, Carlos L. Arteaga, A John Iafrate, Jeffrey Sklar, Richard F. Little, Keith T. Flaherty. NCI-MATCH: A new paradigm in the era of genomic oncology [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr PL03-01.
Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors
Walsh, Dana M. , Mert, İsmail , Jun, Chen , Hou, Xiaonan , Weroha, Saravut J., Walther-António, Marina

Mayo Clinic

Clinical Cancer Research | August 17, 2018 | Volume: 24 | Issue: 15_Supplement | Pages: A70-A70

10.1158/1557-3265.ovca17-a70 Get It

Abstract Ovarian cancer (OC) is the most lethal gynecologic malignancy and the fifth leading cause of cancer death in the United States. Metformin, an antidiabetic drug, has been shown to decrease the risk of mortality in cancer patients, particularly those with OC. Though the drug acts through inhibition of the PI3K/mTOR/AKT pathway, which is commonly altered in OC, knockout of key proteins in the pathway does not attenuate metformin’s antidiabetic effects. Further, intravenous metformin administration is less effective than oral, implying that some crucial interaction takes place in the gut. The gut is home to some 1013 bacterial cells, collectively known as the microbiota. These bacteria play important roles in fermentation of fiber, producing short-chain fatty acids (SCFA) that have positive health benefits, including prevention of metabolic syndrome, bowel disorders, and certain cancers. Mechanistically, SCFAs inhibit the PI3K/mTOR/AKT pathway, similar to metformin. Conditions such as obesity, metabolic syndrome, and diabetes significantly alter gut microbiota composition, possibly leading to a reduction in beneficial SCFAs. However, in type II diabetes, treatment with metformin leads to an increase in SCFA-producing bacteria, suggesting that metformin may positively influence the microbiota to improve patient metabolic profiles. In OC, metformin may play a similar role in promoting the presence of SCFA-producing bacteria. We hypothesized that metformin increases the abundance of SCFA-producing bacteria in the gut, with which it acts synergistically to decrease growth of OC cells in combination with OC chemotherapy. To investigate our hypothesis, we have employed the OC patient-derived xenograft (PDX) mouse model established at Mayo Clinic. Immunocompromised SCID mice received OC cells from Mayo Clinic patients and the tumors were allowed to grow to an appropriate size before treatment was started. Cage mates were split into one of four treatment arms: a control (no treatment) group, metformin only, carboplatin/paclitaxel (CP) chemotherapy only, or CP with metformin. Mice received 2mg/ml metformin in their water continuously and/or 51mg/kg carboplatin and 15mg/kg paclitaxel intravenously weekly. Stool was collected weekly prior to tumor injection, during tumor growth, and through the four weeks of treatment. DNA was extracted from stool and bacterial 16S rRNA amplicon sequencing was used to determine microbiota profiles. Mice with chemosensitive tumors treated with only CP chemotherapy had significant reductions in tumor growth along with significantly less microbial gut diversity than pretumor and pretreatment mice. Chemosensitive mice treated with metformin alone did not lose significant microbial diversity but did not have significant reductions in tumor growth as compared to the control mice. CP in combination with metformin both reduced tumor growth and protected against loss of microbiota diversity. Further, mice treated with only metformin had significant increases in abundance in the Firmicutes genera Ruminococcus and Oscillospira, SCFA producers that are associated with leanness and health. Mice treated with both metformin and CP had significant increases in another SCFA-producing Firmicute, Moryella. Finally, mice with chemoresistant tumors showed improved tumor growth inhibition with combination CP/metformin therapy, suggesting that metformin-associated changes in the gut microbiota may increase sensitivity to CP. These data support the hypothesis that metformin protects against detrimental loss of gut microbiota diversity induced by chemotherapy treatment, enriching beneficial SCFA producers. This work implies a role for the gut microbiota in OC treatment and provides support for metformin’s potential use as a beneficial addition to chemotherapy treatment. Citation Format: Dana M. Walsh, Ismail Mert, Chen Jun, Xiaonan Hou, Saravut John Weroha, Marina Walther-Antonio. Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr A70.
Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Üstün, Celalettin , Pullarkat, Sheeja T. , Yeung, Cecilia C.S. , Broesby‐Olsen, Sigurd , Ohgami, Robert S. , Kim, Young , Vestergaard, Hanne , Chen, Dong , Kluin, Philip M., Dolan, Michelle, Mrózek, Krzysztof , Czuchlewski, David R., Horny, Hans‐Peter, George, Tracy I. , Kristensen, Thomas Kielsgaard , Ku, Nam K., Yi, Cecilia Arana , Møller, Michael , Marcucci, Guido , Hilberink, Jacobien R. , Pullarkat, Vinod , Shanley, Ryan , Kohlschmidt, Jessica, Coulombe, Janie , Salhotra, Amandeep , Soma, Lori , Cho, Christina , Hoermann, Gregor , Nakamura, Ryo , Deeg, Joachim, Bloomfield, Clara D. , Weisdorf, Daniel J. , Litzow, Mark R. , Valent, Peter , Huls, Gerwin , Yeung, Cecilia , Baughn, Linda, Chen, Dong , Møller, Michael Boe , Weisdorf, Dan , George, Tracy I , Arana Yi, Cecilia , Valent, Peter , Morgan, Elizabeth A. , Moodie, Erica E. M. , Sperr, Wolfgang R. , Baughn, Linda B. , Schiefer, Ana-Iris , Linden, Michael A. , Akin, Cem , Gotlib, Jason , Hornick, Jason L. , Nakamura, Ryo, Perales, Miguel‐Angel , Borthakur, Gautam

Mayo Clinic

Cancer Medicine | August 17, 2018 | Volume: 7 | Issue: 9 | Pages: 4447-4455

10.1002/cam4.1733 | PMID 30117318 Get It

AbstractBackgroundAlthough the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease‐free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper‐ or hypodiploidy were included in a scoring system (named I‐CBFit). DFS rate at 2 years was 76% for patients with a low‐risk I‐CBFit score compared with 36% for those with a high‐risk I‐CBFit score (P < 0.0001). Low‐ vs high‐risk OS at 2 years was 89% vs 51% (P < 0.0001).ConclusionsI‐CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low‐risk I‐CBFit score).
Treatment for Rotator Cuff Tear Is Influenced by Demographics and Characteristics of the Area Where Patients Live
Chapman, Cole G. , Floyd, Sarah B. , Thigpen, Charles A. , Tokish, John M. , Chen, Brian , Brooks, John M. , Chen, Brian

Mayo Clinic

JBJS Open Access | August 7, 2018 | Volume: 3 | Issue: 3 | Pages: e0005

10.2106/jbjs.oa.18.00005 | PMID 30533589 Get It

Background: Atraumatic rotator cuff tear is a common orthopaedic complaint for people >60 years of age. Lack of evidence or consensus on appropriate treatment for this type of injury creates the potential for substantial discretion in treatment decisions. To our knowledge, no study has assessed the implications of this discretion on treatment patterns across the United States. Methods: All Medicare beneficiaries in the United States with a new magnetic resonance imaging (MRI)-confirmed atraumatic rotator cuff tear were identified with use of 2010 to 2012 Medicare administrative data and were categorized according to initial treatment (surgery, physical therapy, or watchful waiting). Treatment was modeled as a function of the clinical and demographic characteristics of each patient. Variation in treatment rates across hospital referral regions and the presence of area treatment signatures, representing the extent that treatment rates varied across hospital referral regions after controlling for patient characteristics, were assessed. Correlations between measures of area treatment signatures and measures of physician access in hospital referral regions were examined. Results: Among patients who were identified as having a new, symptomatic, MRI-confirmed atraumatic rotator cuff tear (n = 32,203), 19.8% were managed with initial surgery; 41.3%, with initial physical therapy; and 38.8%, with watchful waiting. Patients who were older, had more comorbidity, or were female, of non-white race, or dual-eligible for Medicaid were less likely to receive surgery (p < 0.0001). Black, dual-eligible females had 0.42-times (95% confidence interval [CI], 0.34 to 0.50) lower odds of surgery and 2.36-times (95% CI, 2.02 to 2.70) greater odds of watchful waiting. Covariate-adjusted odds of surgery varied dramatically across hospital referral regions; unadjusted surgery and physical therapy rates varied from 0% to 73% and from 6% to 74%, respectively. On average, patients in high-surgery areas were 62% more likely to receive surgery than the average patient with identical measured characteristics, and patients in low-surgery areas were half as likely to receive surgery than the average comparable patient. The supply of orthopaedic surgeons and the supply of physical therapists were associated with greater use of initial surgery and physical therapy, respectively. Conclusions: Patient characteristics had a significant influence on treatment for atraumatic rotator cuff tear but did not explain the wide-ranging variation in treatment rates across areas. Local-area physician supply and specialty mix were correlated with treatment, independent of the patient’s measured characteristics.
Reply to Suciuet al.
Xie, Dong , Chen, Chang , Jiang, Gening , Yang, Ping

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | August 4, 2018 | Volume: 55 | Issue: 3 | Pages: 593-594

10.1093/ejcts/ezy261 | PMID 30102317 Get It

Fast gray matter acquisition T1 inversion recovery MRI to delineate the mammillothalamic tract for preoperative direct targeting of the anterior nucleus of the thalamus for deep brain stimulation in epilepsy
Middlebrooks, Erik H. , Stead, Matthew, Lin, Chen , Baydın, Serhat, Middlebrooks, Erik H , Grewal, Sanjeet S. , Kaufmann, Timothy J. , Stead, Matthew, Lundstrom, Brian N. , Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | August 1, 2018 | Volume: 45 | Issue: 2 | Pages: E6

10.3171/2018.4.focus18147 | PMID 30064328 Get It

When medically intractable epilepsy is multifocal or focal but poorly localized, neuromodulation can be useful therapy. One such technique is deep brain stimulation (DBS) targeting the anterior nucleus of the thalamus (ANT). Unfortunately, the ANT is difficult to visualize in standard MRI sequences and its indirect targeting is difficult because of thalamic variability and atrophy in patients with epilepsy. The following study describes the novel use of the fast gray matter acquisition T1 inversion recovery (FGATIR) MRI sequence to delineate the mammillothalamic tract for direct targeting of the ANT through visualizing the termination of the mammillothalamic tract in the ANT. The day prior to surgery in a 19-year-old, right-handed woman with a 5-year history of epilepsy, MRI was performed on a 3-T Siemens Prisma scanner (Siemens AG, Healthcare Sector) using a 64-channel head and neck coil. As part of the imaging protocol, noncontrast magnetization-prepared rapid gradient echo (MP-RAGE) and diffusion tensor imaging (DTI) sequences were obtained for targeting purposes. The ANT was directly targeted using the FGATIR sequence, and bilateral Medtronic 3389 leads were placed. At the last follow-up (2 months), the patient reported an approximate 75% decrease in seizure frequency, as well as a decrease in seizure severity.
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Rambau, Peter , Vierkant, Robert A. , Intermaggio, Maria P., Kelemen, Linda E. , Goodman, Marc T. , Herpel, Esther , Kommoss, Stefan , Jimenez‐Liñan, Mercedes , Menon, Usha , Polo, Susanna Hernando, Reis, Francisco José Cândido dos , Gayther, Simon A. , Sharma, Raghwa , Harnett, Paul R. , Hatfield, Emma, Andrade, Jurandyr Moreira de , Nelson, Gregg , Steed, Helen , Schildkraut, Joellen M. , Carney, Micheal E, Høgdall, Estrid , Whittemore, Alice S. , Widschwendter, Martin , Kennedy, Catherine J. , Armasu, Sebastian M. , Daley, Frances , Coulson, Penny , Jones, Michael E. , Anglesio, Michael S. , Chow, Christine , Fazio, Anna de , García‐Closas, Montserrat , Huzarski, Tomasz , Jensen, Allan , Lubiński, Jan , Oszurek, Oleg, Benı́tez, Javier , Mina, Fady , Staebler, Annette , Taran, Florin‐Andrei , Pasternak, J , Talhouk, Aline , Rossing, Mary Anne, Hendley, Joy , Group, AOCS, Fereday, Sián , Ness, Roberta B., Sieh, Weiva , El‐Bahrawy, Mona , Lester, Jenny , Sinn, Hans‐Peter , Fasching, Peter A. , Chang‐Claude, Jenny , Moysich, Kirsten B. , Bowtell, David D.L. , Luk, Hugh, Shah, Mitul , Jung, Audrey , Alsop, Jennifer , Thompson, Pamela J., Swerdlow, Anthony J. , Karpinskyj, Chloe , García, María J. , Deen, Susha, Palacios, José , Koziak, Jennifer M. , Goode, Ellen L. , Huntsman, David G. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Köbel, Martin , Ramus, Susan J , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Swerdlow, Anthony J , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Anglesio, Michael S , Jones, Michael E , Sieh, Weiva , García-Closas, Montserrat , Benitez, Javier , Høgdall, Estrid , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Fereday, Sian , Lubinski, Jan , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Steed, Helen , Goodman, Marc T , Pharoah, Paul D.P. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Doherty, Jennifer A. , Larson, Melissa C. , Hatfield, Emma, Wang, Frances M. , Wang, Qin , Wang, Chen , Brucker, Sara Yvonne , Cybulski, Cezary , Harris, Holly R. , Hartkopf, Andreas D , Group, AOCS, Edwards, Todd , Modugno, Francesmary , Winham, Stacey J. , Kjær, Susanne K. , Gronwald, Jacek , Hernandez, Brenda Y. , Behrens, Sabine , Ghatage, Prafull , Alsop, Kathryn , García-Donás, Jesús , Cazorla, Alicia , Wilkens, Lynne R. , Berchuck, Andrew , Brenton, James D. , Cook, Linda S.

Mayo Clinic

The Journal of Pathology: Clinical Research | July 30, 2018 | Volume: 4 | Issue: 4 | Pages: 250-261

10.1002/cjp2.109 | PMID 30062862 Get It

AbstractWe aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Lu, Yingchang , Beeghly‐Fadiel, Alicia, Wu, Lang , Li, Bingshan , Schildkraut, Joellen M. , Im, Hae Kyung , Chen, Y. Ann , Permuth, Jennifer B. , Reid, Brett M. , Teer, Jamie K. , Moysich, Kirsten B., Andrulis, Irene L. , Barkardóttir, Rósa B. , Benı́tez, Javier , Caldés, Trinidad , Chang‐Claude, Jenny , Claes, Kathleen , Daly, Mary B., DeFazio, Anna , Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Fasching, Peter A. , Fortner, Renée T. , Fountzilas, George , Friedman, Eitan , Ganz, Patricia A. , Goldgar, David E., Goodman, Marc T. , Greene, Mark H. , Hamann, Ute, Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Claus , Hulick, Peter J. , Huntsman, David G. , Imyanitov, Evgeny N., Jakubowska, Anna , James, Paul A. , Kelemen, Linda E., Kwong, Ava , Le, Nhu D., Lesueur, Fabienne , May, Taymaa, McGuffog, Lesley, McNeish, Iain A. , Merritt, Melissa A. , Montagna, Marco , Ņikitina-Zaķe, Liene , Offit, Kenneth, Oláh, Edith , Olopade, Olufunmilayo I. , Olsson, Håkan , Osório, Ana , Park, Sue K. , Peeters, Petra H.M. , Peterlongo, Paolo , Phelan, Catherine M., Pujana, Miguel Ángel , Ramus, Susan J. , Rennert, Gad , Rodriguez, Gustavo C. , Rodríguez‐Antona, Cristina , Romieu, Isabelle , Rookus, Matti A. , Rossing, Mary Anne, Rzepecka, Iwona K. , Schmutzler, Rita K., Sieh, Weiva , Simard, Jacques , Song, Honglin , Sutphen, Rebecca , Swerdlow, Anthony J. , Teixeira, Manuel R. , Teo, Soo‐Hwang , Thomassen, Mads , Trichopoulou, Antonia , Tworoger, Shelley S. , Rensburg, Elizabeth J. van , Vega, Ana , Edwards, Digna Velez, Webb, Penelope M. , Weitzel, Jeffrey N. , Wentzensen, Nicolas , Wu, Anna H. , Zorn, Kristin K. , Gayther, Simon A. , Antoniou, Antonis C. , Goode, Ellen L. , Chenevix‐Trench, Georgia , Sellers, Thomas A. , Long, Jirong , Durocher, Francine , Eccles, Diana , Permuth, Jennifer B , Teer, Jamie K , Barnes, Daniel R , Caldes, Trinidad , Caligo, Maria A , Chang-Claude, Jenny , Fazio, Anna de , Dennis, Joe , Fasching, Peter A , Fortner, Renée T , Garber, J. E. , Giles, Graham G , Greene, Mark H , Hulick, Peter J , Isaacs, Claudine , James, Paul , Kiemeney, Lambertus A , Kjaer, Susanne K , Leslie, Goska , Lesueur, Fabienne , McNeish, Iain A , Nevanlinna, H , Nussbaum, Robert , Park, Sue K , Parsons, Michael T , Peterlongo, Paolo , Pujana, Miquel Angel , Ramus, Susan J , Rennert, Gad , Rodríguez-Antona, Cristina , Sandler, Dale P , Spurdle, Amanda B , Teixeira, Manuel R , Teo, Soo H , Tworoger, Shelley S , van Rensburg, Elizabeth J , Vanderstichele, Adriaan , Webb, Penelope M , Wolk, Alicja , Dörk, Thilo , Eccles, Diana , Swerdlow, Anthony J , Moysich, Kirsten , Vega, Ana , Weitzel, Jeffrey N , Claes, Kathleen B M , Olopade, Olufunmilayo I , Heitz, Florian , Jakubowska, Anna , Sieh, Weiva , Benitez, Javier , Montagna, Marco , Simard, Jacques , Chenevix-Trench, Georgia , Høgdall, Claus K , Goodman, Marc T , Beeghly‐Fadiel, Alicia , Guo, Xingyi , Moysich, Kirsten B. , Anton‐Culver, Hoda , Arun, Banu , Bandera, Elisa V. , Barnes, Daniel R. , Bjørge, Line , Brenton, James D. , Bützow, Ralf C. , Caligo, Maria A. , Campbell, Ian , Couch, Fergus J. , Cramer, Daniel W. , Dı́ez, Orland , Domchek, Susan M. , Garber, Judy E. , Giles, Graham G. , Godwin, Andrew K. , Gronwald, Jacek , Hildebrandt, Michelle A.T. , Hollestelle, Antoinette , Isaacs, Claudine , Karlan, Beth Y. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Leslie, Goska , Levine, Douglas A. , Mattiello, Amalia , Modugno, Francesmary , Neuhausen, Susan L. , Nevanlinna, Heli , Nielsen, Finn Cilius , Nussbaum, Robert L. , Olson, Sara H. , Parsons, Michael T. , Pejovic, Tanja B. , Risch, Harvey A. , Sandler, Dale P. , Setiawan, Veronica Wendy , Sharma, Priyanka , Singer, Christian F. , Southey, Melissa C. , Spurdle, Amanda B. , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tung, Nadine , Vanderstichele, Adriaan , Edwards, Digna R. Velez , White, Emily , Wolk, Alicja , Yannoukakos, Drakoulis , Berchuck, Andrew , Pharoah, Paul D.P. , Zheng, Wei , Kwong, Ava , Im, H K

Mayo Clinic

Cancer Research | July 27, 2018 | Volume: 78 | Issue: 18 | Pages: 5419-5430

10.1158/0008-5472.can-18-0951 | PMID 30054336 Get It

Abstract Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and causal genes underlying these associations remain largely unknown. Here, we performed a transcriptome-wide association study to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA sequencing data (68 normal ovarian tissue samples from 68 individuals and 6,124 cross-tissue samples from 369 individuals) and high-density genotyping data from European descendants of the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level of P &lt; 2.2 × 10−6, we identified 35 genes, including FZD4 at 11q14.2 (Z = 5.08, P = 3.83 × 10−7, the cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel locus for EOC risk. All other 34 significantly associated genes were located within 1 Mb of known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 genes disappeared and three genes remained (P &lt; 1.47 × 10−3). These data identify one novel locus (FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new insights into EOC carcinogenesis. Significance: Transcriptomic analysis of a large cohort confirms earlier GWAS loci and reveals FZD4 as a novel locus associated with EOC risk. Cancer Res; 78(18); 5419–30. ©2018 AACR.
Reply: Gender-Confirmation Surgery Using the Pedicle Transverse Colon Flap for Vaginal Reconstruction: A Clinical Outcome and Sexual Function Evaluation Study
Manrique, Oscar J. , Sabbagh, M. Diya , Ciudad, Pedro , Adabi, Kian , Huang, Tony Chieh‐Ting , Chen, Hung‐Chi

Mayo Clinic

Plastic & Reconstructive Surgery | July 25, 2018 | Volume: 142 | Issue: 4 | Pages: 606e-608e

10.1097/prs.0000000000004754 | PMID 30045162 Get It